Screener
Relmada Therapeutics, Inc. RLMD Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Prepaid expenses | (402,430) | 290,051 |
| Accounts payable | 1,762,457 | (2,865,553) |
| Accrued expenses | (1,559,361) | (2,194,416) |
| Net cash used in operating activities | (15,067,488) | (18,067,033) |
| Cash flows from investing activities | ||
| Purchase of short-term investments | (149,517,480) | (487,916) |
| Sale of short-term investments | 14,290,483 | 15,847,629 |
| Net cash (used in)/provided by investing activities | (135,226,997) | 15,359,713 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s operating cash flow?
- Relmada Therapeutics, Inc. (RLMD) reported operating cash flow of -$15.07M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Relmada Therapeutics, Inc.'s operating cash flow increased by 16.6% year-over-year, from -$18.07M to -$15.07M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s operating cash flow has grown at a -16.0% compound annual growth rate (CAGR), from -$91.87M to -$45.79M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Relmada Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude